Business Combinations (Narrative) (Details) | 3 Months Ended | 6 Months Ended | 9 Months Ended | | | | |
Oct. 02, 2022 USD ($) | Apr. 03, 2022 USD ($) shares | Oct. 03, 2021 USD ($) $ / shares | Jul. 03, 2022 USD ($) | Oct. 02, 2022 USD ($) | Oct. 03, 2021 USD ($) $ / shares | Jan. 02, 2022 USD ($) employees | Sep. 17, 2021 $ / shares | Jul. 04, 2021 USD ($) | Jan. 03, 2021 USD ($) |
Business Acquisition [Line Items] | | | | | | | | | | |
Number of Years in Measurement Period from Acquisition Date to Change Underlying Assumptions | | | | | 1 year | | | | | |
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value | $ 44,574,000 | | $ 37,225,000 | $ 48,593,000 | $ 44,574,000 | $ 37,225,000 | $ 57,996,000 | | $ 3,334,000 | $ 2,953,000 |
Total transaction costs | (8,500,000) | | (69,900,000) | | (25,900,000) | (72,500,000) | | | | |
Goodwill | 6,373,327,000 | | | | 6,373,327,000 | | 6,627,119,000 | | | |
Business Combination, Contingent Consideration, Liability, Current | 5,300,000 | | | | 5,300,000 | | 1,300,000 | | | |
Business Combination, Contingent Consideration, Liability, Noncurrent | 39,300,000 | | | | 39,300,000 | | 56,700,000 | | | |
Interest Expense | 25,931,000 | | 43,531,000 | | 81,447,000 | 74,407,000 | | | | |
Business Combination, Contingent Consideration, Liability | 44,600,000 | | | | 44,600,000 | | $ 58,000,000 | | | |
Business Combination, Acquisition Related Costs | 8,500,000 | | 69,900,000 | | $ 25,900,000 | 72,500,000 | | | | |
Fiscal Year 2022 Acquisitions [Member] | | | | | | | | | | |
Business Acquisition [Line Items] | | | | | | | | | | |
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | | | | | 5 years | | | | | |
Oxford Immunotec [Member] | | | | | | | | | | |
Business Acquisition [Line Items] | | | | | | | | | | |
Entity Number of Employees | employees | | | | | | | 275 | | | |
Foreign Currency Transaction Gain (Loss), before Tax | | | | | | (5,400,000) | | | | |
Interest Expense | | | | | | 23,600,000 | | | | |
Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member] | | | | | | | | | | |
Business Acquisition [Line Items] | | | | | | | | | | |
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments | | $ (183,000) | | | | | | | | |
Business Combination, Consideration Transferred | | 981,698,000 | | | | | | | | |
Cash Acquired | | (195,010,000) | | | | | | | | |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets | 71,840,000 | | | | $ 71,840,000 | | | | | |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment | | | | | | | $ 26,507,000 | | | |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets | 15,527,000 | | | | 15,527,000 | | | | | |
Cash paid to the shareholders | | 1,128,584,000 | | | | | | | | |
Business Combination, Consideration Transferred, Liabilities Incurred | | $ 2,910,000 | | | | | | | | |
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | | 12 years 3 months 18 days | | | | | | | | |
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value | | | | 45,031,000 | | | | | | |
Goodwill | 545,262,000 | | | | 545,262,000 | | | | | |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt | 61,925,000 | | | | 61,925,000 | | | | | |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net | | | | | | | $ 981,698,000 | | | |
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | | $ 0 | | | | | | | | |
Nexcelom Bioscience [Member] | | | | | | | | | | |
Business Acquisition [Line Items] | | | | | | | | | | |
Entity Number of Employees | employees | | | | | | | 130 | | | |
BioLegend [Member] | | | | | | | | | | |
Business Acquisition [Line Items] | | | | | | | | | | |
Business Acquisition, Pro Forma Revenue | | | 942,568,000 | | | 3,040,295,000 | | | | |
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual | | 91,700,000 | | | | | | | | |
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual | | 25,800,000 | | | | | | | | |
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments | | 0 | | | | | | | | |
Business Combination, Consideration Transferred | | 5,688,964,000 | | | | | | | | |
Cash Acquired | | (292,377,000) | | | | | | | | |
Cash Acquired from Acquisition | | (292,400,000) | | | | | | | | |
Business Acquisition, Cost of Acquired Entity, Consideration Paid in Cash | | 3,300,000,000 | | | | | | | | |
Business Acquisition, Cost of Acquired Entity, Consideration Paid in Common Stock | | 2,600,000,000 | | | | | | | | |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets | | | | | | | $ 184,704,000 | | | |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment | | | | | | | 147,200,000 | | | |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets | | | | | | | $ 9,330,000 | | | |
Entity Number of Employees | employees | | | | | | | 700 | | | |
Cash paid to the shareholders | | 3,336,115,000 | | | | | | | | |
Business Combination, Consideration Transferred, Liabilities Incurred | | $ 6,857,000 | | | | | | | | |
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life | | 16 years 3 months 18 days | | | | | | | | |
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value | | $ 0 | | | | | | | | |
Goodwill | 3,509,931,000 | | | | 3,509,931,000 | | | | | |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt | 37,461,000 | | | | 37,461,000 | | | | | |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net | | | | | | | $ 5,688,964,000 | | | |
Business Acquisition, Pro Forma Income (Loss) from Continuing Operations, Net of Tax | | | $ 170,174,000 | | | $ 749,654,000 | | | | |
Business Acquisition, Pro Forma Earnings Per Share, Basic | $ / shares | | | $ 1,320 | | | $ 5,910 | | | | |
Business Acquisition, Pro Forma Earnings Per Share, Diluted | $ / shares | | | $ 1,320 | | | $ 5,890 | | | | |
Business Acquisition, Share Price | $ / shares | | | | | | | | $ 187.56 | | |
Stock Issued During Period, Shares, Acquisitions | shares | | 14,066,799 | | | | | | | | |
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | | $ 2,638,369,000 | | | | | | | | |
Acquisition-related stock compensation expense | 5,500,000 | | | | 20,200,000 | | | | | |
Cash Acquired from Acquisition | | 292,400,000 | | | | | | | | |
Diagnostics [Member] | | | | | | | | | | |
Business Acquisition [Line Items] | | | | | | | | | | |
Goodwill | 1,899,451,000 | | | | 1,899,451,000 | | 1,970,350,000 | | | |
Discovery & Analytical Solutions [Member] | | | | | | | | | | |
Business Acquisition [Line Items] | | | | | | | | | | |
Goodwill | 4,473,876,000 | | | | 4,473,876,000 | | 4,656,769,000 | | | |
Core Technology [Member] | Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member] | | | | | | | | | | |
Business Acquisition [Line Items] | | | | | | | | | | |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | | | | 290,089,000 | | | | | | |
Core Technology [Member] | BioLegend [Member] | | | | | | | | | | |
Business Acquisition [Line Items] | | | | | | | | | | |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | | | | | | | 782,400,000 | | | |
Customer Relationships [Member] | Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member] | | | | | | | | | | |
Business Acquisition [Line Items] | | | | | | | | | | |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | | | | $ 141,670,000 | | | | | | |
Customer Relationships [Member] | BioLegend [Member] | | | | | | | | | | |
Business Acquisition [Line Items] | | | | | | | | | | |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | | | | | | | 1,714,800,000 | | | |
Trade Names [Member] | Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member] | | | | | | | | | | |
Business Acquisition [Line Items] | | | | | | | | | | |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | $ 39,476,000 | | | | 39,476,000 | | | | | |
Trade Names [Member] | BioLegend [Member] | | | | | | | | | | |
Business Acquisition [Line Items] | | | | | | | | | | |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | | | | | | | $ 38,000,000 | | | |
United States of America, Dollars | Fiscal Year 2022 Acquisitions [Member] | | | | | | | | | | |
Business Acquisition [Line Items] | | | | | | | | | | |
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | | | | | $ 13,300,000 | | | | | |
United States of America, Dollars | Oxford Immunotec [Member] | | | | | | | | | | |
Business Acquisition [Line Items] | | | | | | | | | | |
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | | 590,900,000 | | | | | | | | |
United States of America, Dollars | Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member] | | | | | | | | | | |
Business Acquisition [Line Items] | | | | | | | | | | |
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | | 1,200,000,000 | | | | | | | | |
United States of America, Dollars | Nexcelom Bioscience [Member] | | | | | | | | | | |
Business Acquisition [Line Items] | | | | | | | | | | |
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | | 267,300,000 | | | | | | | | |
United States of America, Dollars | BioLegend [Member] | | | | | | | | | | |
Business Acquisition [Line Items] | | | | | | | | | | |
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | | 5,700,000,000 | | | | | | | | |
United States of America, Dollars | Fiscal Year 2021 Other Acquisitions [Member] | | | | | | | | | | |
Business Acquisition [Line Items] | | | | | | | | | | |
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | | 318,600,000 | | | | | | | | |
Amortization of intangible assets recognized in acquisition [Member] | BioLegend [Member] | | | | | | | | | | |
Business Acquisition [Line Items] | | | | | | | | | | |
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual | | 47,000,000 | | | | | | | | |
Amortization of fair value adjustment to acquired inventory [Member] | BioLegend [Member] | | | | | | | | | | |
Business Acquisition [Line Items] | | | | | | | | | | |
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual | | $ 16,600,000 | | | | | | | | |